Real-World Safety of an Implantable Continuous Glucose Sensor Over Multiple Cycles of Use: A Post-Market Registry Study

Previously, the safety and accuracy of the Eversense continuous glucose monitoring (CGM) system were characterized in three pivotal trials among individuals with type 1 diabetes (T1D) and type 2 diabetes (T2D) with a single 90- or 180-day sensor insertion–removal cycle. The Post-Market Clinical Foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Deiss, Dorothee, Irace, Concetta, Carlson, Grace, Tweden, Katherine S., Kaufman, Francine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945795/
https://www.ncbi.nlm.nih.gov/pubmed/31418587
http://dx.doi.org/10.1089/dia.2019.0159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945795/
https://www.ncbi.nlm.nih.gov/pubmed/31418587
http://dx.doi.org/10.1089/dia.2019.0159

Ejemplares similares